Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Changes of Cerebral Glucose Metabolism and After 12 Weeks of Escitalpram Treatment in Panic Disorder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00767871
Recruitment Status : Completed
First Posted : October 7, 2008
Last Update Posted : July 25, 2011
Sponsor:
Collaborator:
H. Lundbeck A/S
Information provided by:
Samsung Medical Center

Brief Summary:

Panic disorder is one of the most prevalent psychiatric disorders and recently abnormal fear network is known to be implicated in the pathophysiology of panic disorder. The fear network involves many brain regions such as amygdala, hippocampus, periaqueductal gray (PAG), locus coeruleus, parahippocampal gyrus, frontal cortex, and thalamus. Escitalopram, a highly selective serotonin reuptake inhibitor, is usually effective for panic dis order, but there is little information on how escitalopram affects the fear network.

The specific aim of this study is to test the following hypotheses using 18F-FDG positron emission tomography (PET)

  1. Patients with panic disorder will show abnormal activity of the fear network compared to healthy comparison subjects.
  2. Patients with panic disorder will show normalized activity of the fear network after 12-weeks of treatment with escitalopram.
  3. The changes of fear work after the treatment will be associated with psychological variables and neurohormones.

Condition or disease Intervention/treatment Phase
Panic Disorder Drug: Lexapro Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 46 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Changes of Cerebral Glucose Metabolism Associated With the Fear Network Activity Before and After 12 Weeks of Escitalpram Treatment in Panic Disorder
Study Start Date : March 2007
Actual Primary Completion Date : August 2007
Actual Study Completion Date : December 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Panic Disorder

Arm Intervention/treatment
Experimental: Escitalopram
escitalopram (10-20mg) to panic patients
Drug: Lexapro
12 week treatment with lexapro




Primary Outcome Measures :
  1. 18FDG-PET, PDSS & HAM-A [ Time Frame: 12 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • panic disorder
  • 20-60 years

Exclusion Criteria:

  • history of major psychosis (schizophrenia or bipolar disorder), social phobia, obsessive-compulsive disorder, and generalized anxiety disorder, and posttraumatic stress disorder. The acceptable score on the 17-item Hamilton Depression Rating Scale at entry into the study will be less than 17.
  • patients and volunteers with alcohol dependence and current regular use of benzodiazepines will be excluded. Subjects with current or previous regular use of benzodiazepines will be excluded.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00767871


Locations
Layout table for location information
Korea, Republic of
Samsung Medical Center
Seoul, Korea, Republic of, 135-710
Sponsors and Collaborators
Samsung Medical Center
H. Lundbeck A/S
Investigators
Layout table for investigator information
Principal Investigator: Bum-Hee Yu, M.D., Ph.D. Samsung Medical Center

Layout table for additonal information
Responsible Party: Bum-Hee Yu, M.D. Ph.D. / Professor, Department of Psychiatry, Samsung Medical Center
ClinicalTrials.gov Identifier: NCT00767871     History of Changes
Obsolete Identifiers: NCT00461383
Other Study ID Numbers: SMCIRB2007-01-024
First Posted: October 7, 2008    Key Record Dates
Last Update Posted: July 25, 2011
Last Verified: July 2011
Keywords provided by Samsung Medical Center:
Panic disorder
PET
Escitaopram
Additional relevant MeSH terms:
Layout table for MeSH terms
Disease
Panic Disorder
Pathologic Processes
Anxiety Disorders
Mental Disorders
Dexetimide
Citalopram
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Antiparkinson Agents
Anti-Dyskinesia Agents
Parasympatholytics
Autonomic Agents
Peripheral Nervous System Agents
Muscarinic Antagonists
Cholinergic Antagonists
Cholinergic Agents